However, pembrolizumab is applicable to only a minority of patients with pancreatic cancer, because not all patients have tumors that express PD-L1, and the heterogeneity of pancreatic cancer limits its efficacy (61). Here, CD274 is linked to familial pancreatic carcinoma.